COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC.Common Stock Purchase Warrant • May 9th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”, which term shall include any institution that has an account with the Depositary (or a designee appointed by such institution)) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May [•], 20291 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), up to [___] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the
INHIBIKASE THERAPEUTICS, INC. and EQUINITI TRUST COMPANY, LLC, as Warrant Agent Warrant Agency Agreement Dated as of [ ] __, 2024Warrant Agency Agreement • May 9th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
WARRANT AGENCY AGREEMENT, dated as of [ ] __, 2024 (“Agreement”), between Inhibikase Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Equiniti Trust Company, LLC, a limited liability trust company organized under the laws of New York (the “Warrant Agent”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2024, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 9th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
